Supplementary Table 9, column 'Edoxaban', row 'eGFR category', '95 mL/min' (page 15). The cell should be coloured green instead of yellow. It should also read "60 mg"instead of "60 mg (use with caution in 'supranormal' renal function)."In the above-indicated cell, a footnote has also been added to state: "Edoxaban should be used in patients with high creatinine clearance only after a careful evaluation of the individual thromboembolic and bleeding risk."Supplementary Table 9, column 'Edoxaban', row 'Dose reduction in selected patients' (page 16). The cell should read "Edoxaban 60 mg reduced to 30 mg once daily if any of the following: creatinine clearance 15-50 mL/min, body weight <60 kg, concomitant use of dronedarone, erythromycin, ciclosporine or ketokonazole"instead of "Edoxaban 60 mg reduced to 30 mg once daily, and edoxaban 30 mg reduced to 15mg once daily, if any of the following: creatinine clearance of 30-50 mL/min, body weight <60 kg, concomitant us of verapamil or quinidine or dronedarone."

/pdf/2020-esc-guidelines-for-the-diagnosis-and-management-of-38dpic1xu8.pdf

2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS).

Coronary artery disease (CAD) is a pathological process characterized by atherosclerotic plaque accumulation in the epicardial arteries, whether obstructive or non-obstructive. This process can be modified by lifestyle adjustments, pharmacological therapies, and invasive interventions designed to achieve disease stabilization or regression. The disease can have long, stable periods but can also become unstable at any time, typically due to an acute atherothrombotic event caused by plaque rupture or erosion. However, the disease is chronic, most often progressive, and hence serious, even in clinically apparently silent periods. The dynamic nature of the CAD process results in various clinical presentations, which can be conveniently categorized as either acute coronary syndromes (ACS) or chronic coronary syndromes (CCS). The Guidelines presented here refer to the management of patients with CCS. The natural history of CCS is illustrated in Figure 1.

/pdf/2019-esc-guidelines-for-the-diagnosis-and-management-of-5b7mv2v506.pdf

2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes.

Alice K. Jacobs, MD, FACC, FAHA, Chair 

Jeffrey L. Anderson, MD, FACC, FAHA, Chair-Elect 

Nancy Albert, PhD, CCNS, CCRN, FAHA

Mark A. Creager, MD, FACC, FAHA

Steven M. Ettinger, MD, FACC

Robert A. Guyton, MD, FACC

Jonathan L. Halperin, MD, FACC, FAHA

Judith S. Hochman, MD, FACC, FAHA

2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions

http://www.botonimarco.it/files/linee_guida_2011_accf_aha_scai_percutaneus_coronar.pdf

2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention

A correction has been published: European Heart Journal, ehaa895, https://doi.org/10.1093/eurheartj/ehaa895

2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation

Effect of the angiotensin converting enzyme inhibitor trandolapril on functional status and furosemide consumption in patients with reduced left ventricular function after myocardial infarction

1. Brunner-La Rocca [2] 1999 N= 48 Symptoms R = −0.48, p = 0.001 IHD 58%, Non-IHD 42% Treadmill test measuring PVO2 R = −0.31, p < 0.05 2. Krüger [5] 2002 N = 70 Bicycle ergometer measuring PVO2 IHD 40%, Non-IHD 60% R = −0.56, p < 0.001 3. Tjeerdsma [6] 2002 N = 78 NYHA R = 0.83, p < 0.0001 Aetiology unavailable Treadmill test measuring PVO2 R = −0.52, p < 0.001 4. Jourdain [7] 2002 N = 151 NYHA p < 0.001 IHD 63%, Non-IHD 37% 6-MWT (distance) R = −0.69, p < 0.001 5. Kinugawa [3] 2003 N = 84 Bicycle ergometer measuring PVO2 IHD = 17%, Non-IHD 83% R = −0.33, p= NS 6. Wieczorek [8] 2003 N = 44 6-MWT (distance) R = −0.47, p = 0.001 IHD = 57%, Non-IHD 43% Combined meta-analytic result N = 475 Correlation of all exercise variables to BNP IHD = 47%, Non-IHD = 53% (PVO2 and 6-MWT) R = −0.52 N = number, NYHA = New York Heart Association, IHD = Ischaemic heart disease, PVO2 = Peak oxygen uptake, 6-MWT = 6 minutes walk test, NS = not significant, R = correlation coefficient. we also combined the result of the recently published study by the authors (Hogenhuis et al.) on 120 patients before hospital discharge [4] the correlation was even weaker R = −0.41. Our aim was to demonstrate in general that brain natriuretic peptide (BNP) levels are poorly correlated to the functional status and BNP measurement seems not to be a reliable surrogate in this setting; however, we agree with the authors that the clinical setting of patients with heart failure is also important.

BNP and Functional Status in Heart Failure (Response)

Abstract Background An anomalous origin of the right coronary artery from pulmonary artery (ARCAPA) is a very rare coronary anomaly. Case summary A 56-year-old man, presenting haemodynamically unstable due to very rapid atrial fibrillation, was found to have ARCAPA by coronary computed tomography angiography. He had normal left ventricular ejection fraction and without reversible ischaemia on an adenosine stress rubidium positron emission tomography. He was treated solely with betablockers and has been well since. Discussion Numerous case reports on ARCAPA have previously been published, but no previous reports have found rapid atrial fibrillation to be the primary symptom of presentation. Current evidence level concerning the treatment is low; nevertheless, surgical intervention should always be considered to prevent sudden cardiac death. The patient in this case was offered surgical intervention but declined.

/pdf/anomalous-origin-of-the-right-coronary-artery-from-pulmonary-2awf8dum.pdf

Jawdat Abdulla

Papers

Effect of the angiotensin converting enzyme inhibitor trandolapril on functional status and furosemide consumption in patients with reduced left ventricular function after myocardial infarction

BNP and Functional Status in Heart Failure (Response)

Anomalous origin of the right coronary artery from pulmonary artery in an adult presenting with rapid atrial fibrillation: a case report

Coronary CT Angiography as a Guide to Timing of Invasive Treatment in Patients With NSTEACS.

Clinical Course and Therapy Optimization of Patients after Discharge from Heart Failure Clinic - An 'Interventional' Quality Control Study